CN114470201B - 一种装载kcna5抗体的金铂纳米颗粒及其制备方法和应用 - Google Patents
一种装载kcna5抗体的金铂纳米颗粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN114470201B CN114470201B CN202111609438.6A CN202111609438A CN114470201B CN 114470201 B CN114470201 B CN 114470201B CN 202111609438 A CN202111609438 A CN 202111609438A CN 114470201 B CN114470201 B CN 114470201B
- Authority
- CN
- China
- Prior art keywords
- kcna5
- antibody
- gold
- loaded
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 73
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 title claims abstract description 53
- 102100037445 Potassium voltage-gated channel subfamily A member 5 Human genes 0.000 title claims abstract description 53
- JUWSSMXCCAMYGX-UHFFFAOYSA-N gold platinum Chemical compound [Pt].[Au] JUWSSMXCCAMYGX-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 21
- 150000002148 esters Chemical class 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 15
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims abstract description 8
- 239000011258 core-shell material Substances 0.000 claims abstract description 6
- 239000010931 gold Substances 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 12
- 102000004257 Potassium Channel Human genes 0.000 abstract description 6
- 108020001213 potassium channel Proteins 0.000 abstract description 6
- 230000002685 pulmonary effect Effects 0.000 abstract description 6
- 230000002792 vascular Effects 0.000 abstract description 6
- 239000002539 nanocarrier Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 206010021143 Hypoxia Diseases 0.000 description 21
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 230000007954 hypoxia Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 2
- 238000010895 photoacoustic effect Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acoustics & Sound (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种装载KCNA5抗体的金铂纳米颗粒及其制备方法和应用，具体为该纳米颗粒在制备治疗肺动脉高压药物中的应用，所述装载KCNA5抗体的金铂纳米颗粒，包括以下重量百分含量的各组分：Au@Pt纳米颗粒大于90％；KCNA5抗体0.4‑0.6％；活性酯PEG巯基小于10％。本发明结合了KCNA5抗体和纳米技术，构建了负载KCNA5蛋白的纳米药物。核壳结构的纳米载体为靶向药物的负载提供了物理三维空间，在药物传递和纳米动力学方面有优势，同时KCNA5具有肺血管靶向性，该纳米药物可以高效的将KCNA5蛋白递送至肺血管部位，发挥一定肺血管钾通道的功能，缓解肺动脉高压症状。
Description
技术领域
本发明涉及纳米材料技术领域，具体地，涉及一种装载KCNA5抗体的金铂纳米颗粒及其制备方法和应用。
背景技术
纳米级结构材料简称为纳米材料，是指其结构单元的尺寸介于1～100nm范围之间。由于它的尺寸已经接近电子的相干长度，它的性质因为强相干所带来的自组织使得性质发生很大变化。并且，其尺度与可见光处于同一量级，加上其具有大的表面积体积比，因此其所表现的物理特性，例如熔点、磁性、光学、导热、导电特性等等，往往不同于该物质在整体状态时所表现的性质。
Au@Pt纳米颗粒具有核壳结构，外层覆盖较小尺寸的铂纳米颗粒增加纳米材料与底物之间的接触面积，并将铂作为催化中心，可以催化体内过氧自由基(ROS)并转换为氧，从而打开钾离子通道，抑制细胞增生。内核的金纳米颗粒由于等离激元效应可以在红外光照射下发热起到光热转换的作用。而这种热能通过脉冲激光，在金纳米颗粒表面周期性的产生，并引起纳米颗粒尺寸周期性的变化，从而产生光声效应(Photoacoustic Effect)，用来追踪纳米材料在生物体内位置。
KCNA5，钾通道亚家族成员3，已有越来越多的实验证据证明肺动脉平滑肌细胞钾通道功障碍是肺动脉高压的标志，其中KCNA5(Kv1.5)的功能障碍是肺动脉高压发病机制中的关键事件。Stephen L.Archer课题组2003年在Circulation杂志报道：尽管肺动脉高压患者机体仍处于缺氧状态，Kv1.5基因转移将使肺循环正常化，恢复肺血管收缩力和改善肺动脉高压。
发明内容
针对现有技术不足，本发明的目的在于提供一种装载KCNA5抗体的金铂纳米颗粒及其制备方法和应用。
本发明的目的是通过以下技术方案实现的：
第一方面，本发明提供了一种装载KCNA5抗体的金铂纳米颗粒在制备治疗肺动脉高压药物中的应用，所述装载KCNA5抗体的金铂纳米颗粒包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 大于90％；
KCNA5抗体 0.4-0.6％；
活性酯PEG巯基(HS-PEG-NHS) 小于10％。
优选地，所述活性酯PEG巯基的分子量为3500。
优选地，所述装载KCNA5抗体的金铂纳米颗粒包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 95-98％；
KCNA5抗体 0.4-0.6％；
活性酯PEG巯基 1-5％。
第二方面，本发明提供了一种装载KCNA5抗体的金铂纳米颗粒，包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 大于90％；
KCNA5抗体 0.4-0.6％；
活性酯PEG巯基(HS-PEG-NHS) 小于10％。
优选地，所述活性酯PEG巯基的分子量为3500，本发明中采用活性酯PEG巯基的主要作用是通过聚乙二醇一端的巯基连接金、铂纳米颗粒，而聚乙二醇(PEG)另一端是NHS羧基活化基团，用来连接抗体或者药物分子。
优选地，所述装载KCNA5抗体的金铂纳米颗粒包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 95-98％；
KCNA5抗体 0.4-0.6％；
活性酯PEG巯基 1-5％。
第三方面，本发明提供了一种根据权利要求4所述的装载KCNA5抗体的金铂纳米颗粒的制备方法，包括以下步骤：
A、Au@Pt纳米颗粒制备：将氯铂酸和氯金酸配置成溶液后与泊洛沙姆混合，再加入抗坏血酸后进行超声处理，即得Au@Pt纳米颗粒；
B、将KCNA5抗体与活性酯PEG巯基混合后孵育，再加入步骤A制备的Au@Pt纳米颗粒混合后再孵育，即得所述装载KCNA5抗体的金铂纳米颗粒。
优选地，步骤B中，所述KCNA5抗体与活性酯PEG巯基混合后孵育的条件为：先室温下孵育0.5-1.5h，再在0-5℃下孵育12-20h。
优选地，步骤B中，所述加入步骤A制备的Au@Pt纳米颗粒混合后再孵育的条件为：室温下孵育15-25min。
优选地，步骤A中，所述氯铂酸和氯金酸的摩尔比为1:1；
所述超声处理的时间为12-18mins。
本发明通过将KCNA5抗体与金铂纳米颗粒结合，使抗体与病人基因表达的受体定向结合，有利于形成靶向药物治疗，减少对正常细胞的损害和药物剂量的节约。同时利用铂纳米颗粒的催化作用，消耗体内自由基产生活性氧打开钾离子通道抑制细胞增生。目前传统只含抗体的靶向药物无法实现跟踪效果，因此我们设计的金属载体纳米颗粒中含有的金纳米颗粒能够光热光声成像作用，除此之外整个核壳结构提供更大抗体结合表面积优势，由此实现一加一大于二的效果。因此本发明通过KCNA5抗体与金纳米颗粒、铂纳米颗粒制备的结合药物是一种将靶向驱动、药物治疗、成像检测三位一体的治疗药物。
与现有技术相比，本发明具有如下有益效果：
本发明结合了KCNA5抗体和纳米技术，构建了负载KCNA5蛋白的纳米药物。核壳结构的纳米载体为靶向药物的负载提供了物理三维空间，在药物传递和纳米动力学方面有优势，同时KCNA5具有肺血管靶向性，该纳米药物可以高效的将KCNA5蛋白递送至肺血管部位，发挥一定肺血管钾通道的功能，缓解肺动脉高压症状。
附图说明
通过阅读参照以下附图对非限制性实施例所作的详细描述，本发明的其它特征、目的和优点将会变得更明显：
图1为本发明实施例1制备得到的Au@Pt-Kv1.5纳米颗粒表征；其中图1A为Au@Pt-Kv1.5纳米颗粒尺寸和透射电镜图(scale bar＝50nm)；图1B为透射电镜图(scale bar＝100nm)；图1C为紫外可见吸收光谱图；
图2为Au@Pt-Kv1.5纳米颗粒的制备流程；
图3为实施例2中各实验组处理PAMSC细胞后的荧光强度对比结果；
图4为实施例3中模型小鼠的右心室超声结果；其中，上图为右心室长轴图，下图为肺动脉血流过肺动脉瓣图；
图5为实施例3中模型小鼠的PAT/PET比值。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动的前提下所获得的所有其他实施例，都属于本发明保护的范围。
以下实施例中提供了一种装载KCNA5抗体的金铂纳米颗粒，包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 大于90％；
KCNA5抗体 0.4-0.6％；
活性酯PEG巯基(HS-PEG-NHS) 小于10％。
以下实施例中还提供了一种装载KCNA5抗体的金铂纳米颗粒的制备方法，包括以下步骤：
A、Au@Pt纳米颗粒制备：将氯铂酸和氯金酸配置成溶液后与泊洛沙姆混合，再加入抗坏血酸后进行超声处理，即得Au@Pt纳米颗粒；
B、将KCNA5抗体与活性酯PEG巯基混合后孵育，再加入步骤A制备的Au@Pt纳米颗粒混合后再孵育，即得所述装载KCNA5抗体的金铂纳米颗粒。
步骤B中，所述KCNA5抗体与活性酯PEG巯基混合后孵育的条件为：先室温下孵育0.5-1.5h，再在0-5℃下孵育12-20h。
步骤B中，所述加入步骤A制备的Au@Pt纳米颗粒混合后再孵育的条件为：室温下孵育15-25min。
步骤A中，所述氯铂酸和氯金酸的摩尔比为1:1；
所述超声处理的时间为12-18mins。
在上述条件下，均能制备得到本发明所述的装载KCNA5抗体的金铂纳米颗粒，下述实施例中不再进行一一列举。
下面结合附图和具体实施例对本发明作进一步说明，但不作为对本发明的限定。
实施例1、Au@Pt-Kv1.5纳米颗粒的制备
本实施例提供一种装载KCNA5抗体的金铂纳米颗粒，按以下重量百分比含量配置各组分：
Au@Pt纳米颗粒 96.15％；
KCNA5抗体 0.5％；
活性酯PEG巯基 3.35％。
所述装载KCNA5抗体的金铂纳米颗粒的制备工艺如图2所示，具体步骤如下：
第一步：将氯铂酸和氯金酸粉末分别加入去离子水配制成25mM的氯铂酸溶液和氯金酸溶液，将制备的氯铂酸溶液和氯金酸溶液各1毫升与0.06g泊洛沙姆混合。随后向混合液中加入6ml浓度为0.1M的抗坏血酸溶液。超声处理15mins。室温放置24h。
第二步：将155μg活性酯PEG巯基(分子量为3500)粉末加入到44.5μl浓度为0.1M的HEPES缓冲液中，立即用漩涡混合器混合。室温放置30mins后加入74.5μl浓度为310μg/ml的KCNA5抗体，室温孵育1h，再在4℃冰箱中孵育过夜。
第三步：取100μl第一步制得的混合液在12500rpm下离心10mins，倒掉上层清液再加入乙醇重新分散，重复离心洗涤3次。得到的金铂纳米颗粒沉淀(即Au@Pt纳米颗粒)重新分散在500μl浓度为0.1M的HEPES缓冲液中，用漩涡混合器混合均匀并超声分散处理15mins。在得到的分散液中加入52μl第二步制成的混合液，用漩涡混合器混合均匀，并在室温下孵育20mins。
本实施例成功合成了装载KCNA5抗体的金铂纳米颗粒(Au@Pt-Kv1.5)，在形貌上使用电子透射显微镜进行了表征，纳米颗粒(Au@Pt-Kv1.5)大小在50nm左右(图1A)，并呈现明显的核壳结构(图1B)。紫外可见吸收光谱的测试显示纳米颗粒(Au@Pt-Kv1.5)在红外区域有一定的吸收(图1C)。
实施例2、体外PAMSC实验验证
2.1实验材料
本实施例中采用的大鼠肺动脉平滑肌细胞为PAMSC,由ATCC公司,ScienCell提供；Kv1.5抗体购自proteintech公司。
2.2实验方法
提前将PAMSC细胞放在由3％O2，2％CO2，95％N2组成的低氧培养箱内培养24小时作为低氧组PAMSC，常氧条件下培养的PAMSC作为常氧组PAMSC。将常氧组PAMSC和低氧组PAMSC中分别加入溶媒作为对照组1(图3中的Control+Vehicle组)和对照组2(图3中的Hypoxia+Vehicle组)，将低氧组PAMSC中分别加入Au@Pt-Kv1.5(图3中的Au@Pt-Kv1.5+Hypoxia组)，Au@Pt(图3中的Au@Pt+Hypoxia组)作用2小时后，各处理组分别用PBS洗涤，免疫荧光固定液固定10min，Kv1.5抗体4℃敷育过夜；第二天，再用PBST洗涤，用相应的二抗常温敷育1小时，洗涤，共聚焦显微镜(蔡司Zeiss LSM880)20x拍照，Image J软件分析数据。
2.3实验结果
如图3所示，与常氧组PAMSC相比，低氧组PAMSC的Kv1.5荧光强度明显下降。给予Au@Pt-Kv1.5干预2小时后，低氧组PAMSC中Kv1.5荧光强度明显增加(图3)，而给予Au@Pt干预的低氧组PAMSC中Kv1.5荧光强度基本未增加。提示Au@Pt-Kv1.5纳米颗粒在体外PAMSC中的有效性。
实施例3、体内实验验证
构建小鼠肺高压模型，具体步骤为：C57BL6近交系小鼠,8-10周龄，雄性，20±2.5g。置于常压低氧舱中，舱内氧浓度维持在10％，持续3周，且每周第一天皮下注射SU541620mg/kg。SU5416：血管生成抑制剂，血管内皮生长因子受体2抑制剂；购于Sigma-Aldrich。
处理方法为：对照组(Control)置于常压常氧条件下；低氧加纳米载体组(Hypoxia+Au@Pt)先间隔三天腹腔注射含金铂纳米颗粒溶液(即Au@Pt纳米颗粒)(4.0mg/kg)两次后置于常压低氧舱中；纳米抗体组(hypoxia+Au@Pt-Kv1.5)先间隔三天腹腔注射含装载KCNA5抗体的金铂纳米颗粒溶液两次(Au@Pt-Kv1.5)(4.0mg/kg)后置于常压低氧舱中。三组饲料、光照等其他条件一致。
如图4所示，与对照组(Control)相比，低氧加纳米载体组(Hypoxia+Au@Pt)的右心室功能下降，而给予纳米抗体(hypoxia+Au@Pt-Kv1.5)干预后，可以部分逆转低氧诱导的小鼠右心室功能下降。
同时，如图5所示，与对照组(Control)相比，低氧加纳米载体组(Hypoxia+Au@Pt)的PAT/PET比值明显下降，而给予纳米抗体组(hypoxia+Au@Pt-Kv1.5)干预后，可以部分逆转低氧诱导的小鼠PAT/PET的下降。提示纳米抗体(Au@Pt-Kv1.5)对低氧诱导的肺高压有一定的保护作用。
以上所述仅为本发明较佳的实施例，并非因此限制本发明的实施方式及保护范围，对于本领域技术人员而言，应当能够意识到凡运用本发明说明书及图示内容所作出的等同替换和显而易见的变化所得到的方案，均应当包含在本发明的保护范围内。
Claims (5)
1.一种装载KCNA5抗体的金铂纳米颗粒在制备治疗肺动脉高压药物中的应用，其特征在于，所述装载KCNA5抗体的金铂纳米颗粒包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 大于90%；
KCNA5抗体 0.4-0.6%；
活性酯PEG巯基 小于10%；
所述金铂纳米颗粒具有核壳结构；
所述活性酯PEG巯基的分子量为3500；
所述装载KCNA5抗体的金铂纳米颗粒的制备方法，包括以下步骤：
A、Au@Pt纳米颗粒制备：将氯铂酸和氯金酸配置成溶液后与泊洛沙姆混合，再加入抗坏血酸后进行超声处理，即得Au@Pt纳米颗粒；
B、将KCNA5抗体与活性酯PEG巯基混合后孵育，再加入步骤A制备的Au@Pt纳米颗粒混合后再孵育，即得所述装载KCNA5抗体的金铂纳米颗粒。
2.根据权利要求1所述的应用，其特征在于，所述装载KCNA5抗体的金铂纳米颗粒包括以下重量百分含量的各组分：
Au@Pt纳米颗粒 95-98%；
KCNA5抗体 0.4-0.6%；
活性酯PEG巯基 1-5%。
3.根据权利要求1所述的应用，其特征在于，步骤B中，所述KCNA5抗体与活性酯PEG巯基混合后孵育的条件为：先室温下孵育0.5-1.5h，再在0-5℃下孵育12-20h。
4.根据权利要求1所述的应用，其特征在于，步骤B中，所述加入步骤A制备的Au@Pt纳米颗粒混合后再孵育的条件为：室温下孵育15-25min。
5.根据权利要求1所述的应用，其特征在于，步骤A中，所述氯铂酸和氯金酸的摩尔比为1:1；
所述超声处理的时间为12-18mins。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111609438.6A CN114470201B (zh) | 2021-12-24 | 2021-12-24 | 一种装载kcna5抗体的金铂纳米颗粒及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111609438.6A CN114470201B (zh) | 2021-12-24 | 2021-12-24 | 一种装载kcna5抗体的金铂纳米颗粒及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114470201A CN114470201A (zh) | 2022-05-13 |
| CN114470201B true CN114470201B (zh) | 2024-03-19 |
Family
ID=81495597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111609438.6A Active CN114470201B (zh) | 2021-12-24 | 2021-12-24 | 一种装载kcna5抗体的金铂纳米颗粒及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470201B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405652A1 (en) * | 2002-09-27 | 2004-03-27 | University Of Alberta | Augmentation of k+ channel expression using adenoviral vectors |
| JP2009120901A (ja) * | 2007-11-14 | 2009-06-04 | Ne Chemcat Corp | 金−白金コアシェルナノ粒子のコロイド、及びその製造法 |
| CN107469081A (zh) * | 2017-08-15 | 2017-12-15 | 西安交通大学 | 靶向PEG修饰的金纳米棒与AlpcS4偶联的结合体及其制备、应用和抗肿瘤组合物 |
| CN113502326A (zh) * | 2021-09-10 | 2021-10-15 | 中日友好医院(中日友好临床医学研究所) | 基于生物标志物的肺动脉高压的诊断产品及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100119608A1 (en) * | 2008-11-11 | 2010-05-13 | Jinhyuk Fred Chung | Synthesis of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles |
| RU2617055C2 (ru) * | 2011-03-30 | 2017-04-19 | Клин Наномедисин, Инк. | Новые суспензии основанных на золоте и платине биметаллических нанокристаллов, электрохимические способы их производства и их применения |
-
2021
- 2021-12-24 CN CN202111609438.6A patent/CN114470201B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405652A1 (en) * | 2002-09-27 | 2004-03-27 | University Of Alberta | Augmentation of k+ channel expression using adenoviral vectors |
| JP2009120901A (ja) * | 2007-11-14 | 2009-06-04 | Ne Chemcat Corp | 金−白金コアシェルナノ粒子のコロイド、及びその製造法 |
| CN107469081A (zh) * | 2017-08-15 | 2017-12-15 | 西安交通大学 | 靶向PEG修饰的金纳米棒与AlpcS4偶联的结合体及其制备、应用和抗肿瘤组合物 |
| CN113502326A (zh) * | 2021-09-10 | 2021-10-15 | 中日友好医院(中日友好临床医学研究所) | 基于生物标志物的肺动脉高压的诊断产品及其应用 |
Non-Patent Citations (6)
| Title |
|---|
| MASASHI KAJITA et al.Platinum nanoparticle is a useful scavenger of superoxide anion and hydrogen peroxide.《Free Radical Research》.2007,第41卷摘要、第616页右栏. * |
| Michał Zuk et al.Hybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy.《pharmaceutics》.2021,第13卷摘要、2.3-2.4小节. * |
| Porous Au@Pt Nanoparticles: Therapeutic Platform for Tumor Chemo-Photothermal Co-Therapy and Alleviating Doxorubicin-Induced Oxidative Damage;Qian Yang et al;《ACS Appl. Mater. Interfaces》;第10卷 * |
| Stephen L. Archer et al.Preferential Expression and Function of Voltage-Gated, O2-Sensitive K Channels in Resistance Pulmonary Arteries Explains Regional Heterogeneity in Hypoxic Pulmonary Vasoconstriction.《Circulation Research》.2004,全文. * |
| 徐大春.《细胞外超氧化物岐化酶在野百合碱与低氧诱导的肺动脉高压模型中的作用研究》.同济大学出版社,2019,第3-5页. * |
| 李秋等.电压门控钾通道在低氧肺动脉高压中的作用.《医学前言》.2011,第40卷"三、Kv通道与低氧肺动脉高压的关系"小节. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114470201A (zh) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feng et al. | Advances in smart mesoporous carbon nanoplatforms for photothermal–enhanced synergistic cancer therapy | |
| Kim | Nanotechnology platforms and physiological challenges for cancer therapeutics | |
| Yu et al. | Glutathione-activated DNA-Au nanomachine as targeted drug delivery platform for imaging-guided combinational cancer therapy | |
| Khan et al. | A review on nanotechnology: Properties, applications, and mechanistic insights of cellular uptake mechanisms | |
| Jiang et al. | Advances and challenges of nanotechnology-based drug delivery systems | |
| Chow et al. | Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment | |
| Rao | Shedding light on tumors using nanoparticles | |
| Madani et al. | A new era of cancer treatment: carbon nanotubes as drug delivery tools | |
| Wang et al. | Biomineralization: An opportunity and challenge of nanoparticle drug delivery systems for cancer therapy | |
| Lu et al. | Recent advances in multi-configurable nanomaterials for improved chemodynamic therapy | |
| Ruan et al. | Nanomaterials for tumor hypoxia relief to improve the efficacy of ROS-generated cancer therapy | |
| Yao et al. | Application of organic frame materials in cancer therapy through regulation of tumor microenvironment | |
| Hu et al. | Photothermal effect enhancing graphene quantum dots/semiconducting polymer/nanozyme-mediated cancer catalytic therapy | |
| Yao et al. | Applications and safety of gold nanoparticles as therapeutic devices in clinical trials | |
| Zhang et al. | Noble metal nanoparticles: Synthesis, and biomedical implementations | |
| Wu et al. | A bacteria-inspired morphology genetic biomedical material: self-propelled artificial microbots for metastatic triple negative breast cancer treatment | |
| Li et al. | Biocatalysis of MnO2-mediated nanosystem for enhanced multimodal therapy and real-time tracking | |
| Zhang et al. | Recent advances in dual-and multi-responsive nanomedicines for precision cancer therapy | |
| Xiang et al. | Biocompatible AuPd@ PVP core-shell nanoparticles for enhancement of radiosensitivity and photothermal cancer therapy | |
| Tang et al. | Two birds with one stone: innovative ceria-loaded gold@ platinum nanospheres for photothermal-catalytic therapy of tumors | |
| Sun et al. | Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration | |
| Zhang et al. | Biomimetic nanomaterials triggered ferroptosis for cancer theranostics | |
| Nan et al. | Direct modification of extracellular vesicles and its applications for cancer therapy: a mini-review | |
| Tan et al. | Advances in inorganic-based colloidal nanovehicles functionalized for nitric oxide delivery | |
| Wang et al. | Design and fabrication of cascade novel Fenton catalytic nanocomposite as theranostic agent for chemodynamic/photothermal synergistic tumor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Hou Cuilan Inventor after: Song Chengdie Inventor after: Xiao Tingting Inventor after: Chen Shun Inventor after: Dong Liuchang Inventor after: Zhang Yingyue Inventor after: Zhao Qun Inventor before: Song Chengdie Inventor before: Hou Cuilan Inventor before: Xiao Tingting Inventor before: Chen Shun Inventor before: Dong Liuchang Inventor before: Zhang Yingyue Inventor before: Zhao Qun |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |